Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TAK-700 + ADT + RT vs ADT + RT in High Risk Prostate Cancer
NCT01546987Phase 3Completed
- Sponsor
- NRG Oncology
- Start
- May 2012
- Primary completion
- Nov 2021
- Modality
- Small Molecules
- Countries
- 2
01
Overview
A Phase 3 trial of orteronel in prostate cancer (PCa), sponsored by NRG Oncology. Started May 2012; status: completed.
02
Drugs
orteronel
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on NCT01546987.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01546987.